Bloomberg Law
Pharmaceutical & Life Sciences
LinkedIn

Vir Biotech Wins Expedited Regulatory Statuses from FDA, EMA

December 12, 2024, 9:12 PM UTC
Cameron Baker
Cameron Baker

Vir Biotechnology got US FDA breakthrough therapy designation and EMA priority medicine status for Tobevibart and Elebsiran in chronic hepatitis delta (CHD).

  • Phase 3 Eclipse registrational program in CHD to start in 1H25

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in Boston at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2024 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.